World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 17 October 2023
Main ID:  JPRN-UMIN000001798
Date of registration: 25/03/2009
Prospective Registration: No
Primary sponsor: Team RA, Rheumatosurgery, Osaka City University Medical School
Public title: Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study)
Scientific title: Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study) - PRECEPT study
Date of first enrolment: 2008/07/01
Target sample size: 100
Recruitment status: Complete: follow-up complete
URL:  https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001448
Study type:  Interventional
Study design:  Parallel Randomized  
Phase:  Not applicable
Countries of recruitment
Japan
Contacts
Name:     Tatsuya Koike
Address:  Abenoku Asahimachi 1-4-3, Osaka, 545-8585, Japan Japan
Telephone: 06-6645-3984
Email: tatsuya@med.osaka-cu.ac.jp
Affiliation:  Osaka City University Medical School Rheumatosurgery
Name:     Tatsuya Koike
Address:  Abenoku Asahimachi 1-4-3, Osaka, 545-8585, Japan Japan
Telephone: 06-6645-3984
Email:
Affiliation:  Osaka City University Medical School Rheumatosurgery
Key inclusion & exclusion criteria
Inclusion criteria:
Exclusion criteria: Cases who have Joint destruction on hand and foot, in whom we can't measure modified Sharp score. Except Eetanercept dose, there is no restriction for other medicine use.

Age minimum: 20years-old
Age maximum: 80years-old
Gender: Male and Female
Health Condition(s) or Problem(s) studied
Rheumatoid arthritis
Intervention(s)
Injection of etanercept by 50 mg/week for one year
Injection of etanercept by 25 mg/week for one year
Primary Outcome(s)
Total Sharp score (erosion and joint space narrowing)
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Rheumatosurgery, Osaka City University Medical School
Secondary Sponsor(s)
Ethics review
Status: YES
Approval date:
Contact:
Results
Results available: Yes
Date Posted:
Date Completed: 01/03/2011
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey